High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.

Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-

COVID-19*/prevention & control ; Influenza Vaccines*; Humans ; Male ; Middle Aged ; Female ; COVID-19 Vaccines ; Australia/epidemiology ; Vaccination

Background: Previous studies have reported high COVID-19 vaccine hesitancy among people who inject drugs. We aimed to examine COVID-19 vaccine coverage, motivations and barriers to vaccination, and factors associated with uptake among this population in Australia, 1.5 years after vaccine rollout commenced.
Methods: In June-July 2022, 868 people (66.0 % male, mean age 45.6 years) who regularly inject drugs and reside in an Australian capital city reported the number of COVID-19 vaccine doses they had received and their primary motivation (if vaccinated) or barrier (if unvaccinated) to receive the vaccine. We compared vaccine uptake to Australian population estimates and used logistic regression to identify factors associated with ≥ 2 dose and ≥ 3 dose uptake.
Results: Overall, 84.1 % (n = 730) had received at least one COVID-19 vaccine dose, 79.6 % (n = 691) had received ≥ 2 doses, and 46.1 % (n = 400) had received ≥ 3 doses. Participants were less likely to be vaccinated than the Australian general population (prevalence ratio: 0.82, 95 % confidence interval [CI]: 0.76-0.88). Key motivations to receive the vaccine were to protect oneself or others from COVID-19, while barriers pertained to vaccine or government distrust. Opioid agonist treatment (adjusted odds ratio [aOR]: 2.49, 95 % CI: 1.44-4.42), current seasonal influenza vaccine uptake (aOR: 6.76, 95 % CI: 3.18-16.75), and stable housing (aOR: 1.58, 95 % CI: 1.02-2.80) were associated with receipt of at least two vaccine doses. Participants aged ≥ 40 years (versus < 40 years; aOR: 1.66, 95 % CI: 1.10-2.53) or who reported a chronic health condition (aOR: 1.71, 95 % CI: 1.18-2.47) had higher odds of receiving at least three vaccine doses.
Conclusion: We observed higher COVID-19 vaccine uptake than expected given previous studies of vaccine acceptability among people who inject drugs. However, it was lower than the general population. People who inject drugs and reside in unstable housing are a subpopulation that require support to increase vaccine uptake.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Sarah Larney reports a relationship with Gilead Sciences that includes: consulting or advisory. Gregory J. Dore reports a relationship with Gilead Sciences that includes: funding grants. Gregory J. Dore reports a relationship with AbbVie Ltd that includes: funding grants. Raimondo Bruno reports a relationship with Mundipharma International Limited that includes: funding grants. Raimondo Bruno reports a relationship with Indivior that includes: funding grants. Amy Peacock reports a relationship with Seqirus Inc that includes: funding grants. Amy Peacock reports a relationship with Mundipharma International Limited that includes: funding grants.].
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Keywords: COVID-19; COVID-19 vaccines; People who inject drugs; Substance use; Vaccine hesitancy

0 (COVID-19 Vaccines)
0 (Influenza Vaccines)

Date Created: 20240322 Date Completed: 20240416 Latest Revision: 20240416

20240416

10.1016/j.vaccine.2024.03.051

38519346